Literature DB >> 10455304

An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart.

J C Docherty1, B Kuzio, J A Silvester, J Bowes, C Thiemermann.   

Abstract

The cardioprotective properties of inhibition of poly (ADP-ribose) synthetase (PARS) were investigated in the isolated perfused heart of the rat. Hearts were perfused in the Langendorff mode and subjected to 23 min total global ischaemia and reperfused for 60 min. Left ventricular function was assessed by means of an intra-ventricular balloon. High energy phosphates were measured by 31P-NMR spectroscopy. Intracellular levels of NAD were measured by capillary electrophoresis of perchloric acid extracts of hearts at the end of reperfusion. Reperfusion in the presence of the PARS inhibitor 1,5 didroxyisoquinoline (ISO, 100 microM) attenuated the mechanical dysfunction observed following 1 h of reperfusion; 27+/-13 and 65+/-8% recovery of preischaemic rate pressure product for control and 100 microM ISO, respectively. This cardioprotection was accompanied by a preservation of intracellular high-energy phosphates during reperfusion; 38+/-2 vs 58+/-4% (P<0.05) of preischaemic levels of phosphocreatine (PCr) for control and 100 microM ISO respectively and 23+/-1 vs 31+/-3% (P < 0.05) of preischaemic levels of ATP for control and 100 microM ISO respectively. Cellular levels of NAD were higher in ISO treated hearts at the end of reperfusion; 2.56+/-0.45 vs 4.76+/-1.12 micromoles g(-1) dry weight (P<0.05) for control and ISO treated. These results demonstrate that the cardioprotection afforded by inhibition of PARS activity with ISO is accompanied by a preservation of high-energy phosphates and cellular NAD levels and suggest that the mechanism responsible for this cardioprotection may involve prevention of intracellular ATP depletion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455304      PMCID: PMC1760665          DOI: 10.1038/sj.bjp.0702705

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  DNA strand breaks, NAD metabolism, and programmed cell death.

Authors:  D A Carson; S Seto; D B Wasson; C J Carrera
Journal:  Exp Cell Res       Date:  1986-06       Impact factor: 3.905

2.  Inhibition of apoptosis after ischemia-reperfusion in rat myocardium by cycloheximide.

Authors:  S Musat-Marcu; H E Gunter; B I Jugdutt; J C Docherty
Journal:  J Mol Cell Cardiol       Date:  1999-05       Impact factor: 5.000

3.  Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress.

Authors:  J Bowes; M C McDonald; J Piper; C Thiemermann
Journal:  Cardiovasc Res       Date:  1999-01       Impact factor: 10.787

4.  Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.

Authors:  S R Jolly; W J Kane; M B Bailie; G D Abrams; B R Lucchesi
Journal:  Circ Res       Date:  1984-03       Impact factor: 17.367

5.  Relationship between adenine nucleotide metabolism and irreversible ischemic tissue damage in isolated perfused rat heart.

Authors:  T C Vary; E T Angelakos; S W Schaffer
Journal:  Circ Res       Date:  1979-08       Impact factor: 17.367

6.  Ischemia and reperfusion-induced arrhythmias in the rat. Effects of xanthine oxidase inhibition with allopurinol.

Authors:  A S Manning; D J Coltart; D J Hearse
Journal:  Circ Res       Date:  1984-10       Impact factor: 17.367

7.  Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide.

Authors:  I U Schraufstatter; D B Hinshaw; P A Hyslop; R G Spragg; C G Cochrane
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

Review 8.  Poly(ADP-ribose) in the cellular response to DNA damage.

Authors:  N A Berger
Journal:  Radiat Res       Date:  1985-01       Impact factor: 2.841

9.  Role of glycolytic products in damage to ischemic myocardium. Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts.

Authors:  J R Neely; L W Grotyohann
Journal:  Circ Res       Date:  1984-12       Impact factor: 17.367

10.  Energy metabolism in the ischemic heart.

Authors:  M J Rovetto
Journal:  Tex Rep Biol Med       Date:  1979
View more
  13 in total

1.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

3.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

Review 4.  Nitrosative stress and pharmacological modulation of heart failure.

Authors:  Pal Pacher; Richard Schulz; Lucas Liaudet; Csaba Szabó
Journal:  Trends Pharmacol Sci       Date:  2005-06       Impact factor: 14.819

5.  Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.

Authors:  L Liaudet; L Timashpolsky; L Virág; A Cziráki; C Szabó
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 6.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

7.  Hsp70 attenuates hypoxia/reoxygenation-induced activation of poly(ADP-ribose) synthetase in the nucleus of adult rat cardiomyocytes.

Authors:  Kouichi Tanonaka; Wakako Toga; Masaya Takahashi; Ken-ichiro Kawana; Yuki Miyamoto; Hiroyuki Yoshida; Satoshi Takeo
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

8.  A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.

Authors:  David A Morrow; Chaim M Brickman; Sabina A Murphy; Kenneth Baran; Ricardo Krakover; Harold Dauerman; Sujatha Kumar; Natanya Slomowitz; Laura Grip; Carolyn H McCabe; Andrew L Salzman
Journal:  J Thromb Thrombolysis       Date:  2008-06-06       Impact factor: 2.300

Review 9.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007

10.  Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo.

Authors:  Emanuela Masini; Salvatore Cuzzocrea; Emanuela Mazzon; Cosimo Marzocca; Pier Francesco Mannaioni; Daniela Salvemini
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.